Clinical Trial Update: A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIa trial evaluating autologous SLAMF7 CAR-T cells for feasibility, safety, and antitumor activity in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous SLAMF7 CAR-T cells

Snippet

Sponsor: Wuerzburg University Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING